Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2021-04-16Est. Completion: 2028-12
Enrollment target: 210 participants
Locations
University of Bonn, Bonn, Germany
University Medical Center Hamburg Eppendorf, Hamburg, Germany
Eye Clinic Ludwigshafen, Ludwigshafen, Germany
Ludwig Maximilians-University München, München, Germany
Augenzentrum am St. Franziskus-Hospital Münster, Münster, Germany
Knappschaft Kliniken Saar GmbH, Sulzbach, Sulzbach, Germany
Ulm University Hospital, Ulm, Germany
University hospital of Würzburg, Würzburg, Germany
The Institute of Eye Surgery, Waterford, Ireland
RadboudUMC, Nijmegen, Netherlands
Rottherdam ophtalmic institute, Rotterdam, Netherlands
Ophthalmology Clinic Jasne Błonia, Lodz, Poland
Warsaw Ophthalmology Hospital, Warsaw, Poland
Hospital Vall d'Hebron, Barcelona, Spain
University Hospital Bern, Bern, Switzerland
Jules-Gonin Hospital, Lausanne, Switzerland
Mid and South Essex NHS Foundation Trust, Chelmsford, Essex, United Kingdom
Kent & Canterbury Hospital (East Kent University), Canterbury, Kent, United Kingdom
Other microbiome trials you might be interested in